International Journal of Clinical Practice

Review Article

A Network Meta-Analysis of Two Doses of Recombinant Human Thrombopoietin for Treating Sepsis-Related Thrombocytopenia

Table 1

Baseline characteristics of included studies.


Study	Sample size	Proportion of male patients, %	Age, years	The level of PLT, 10⁹/L	APACHE II	Interventions
Study	Sample size	Proportion of male patients, %	Age, years	The level of PLT, 10⁹/L	APACHE II	rhTPO	Comparison

Feng, et al., 2018 [40]	52 vs 25	59.6 vs 64.0	(51.19 ± 18.17) vs (49.62 ± 20.54)	(42.19 ± 8.6) vs (43.07 ± 10.01)	(23.5 ± 3.7) vs (22.6 ± 2.9)	15000 U/d	400 mg/kg IVIG
Chen, 2015 [38]	45 vs 45	57.8 vs 64.4	(53.9 ± 11.6) vs (53.5 ± 11.7)	<50	n.a.	300 U/kg/d	400 mg/kg IVIG
Li, 2015 [42]	32 vs 35	62.5 vs 45.7	(58.56 ± 25.43) vs (59.09 ± 23.89)	(36.93 ± 5.50) vs (35.26 ± 4.71)	(26.94 ± 5.74) vs (24.03 ± 6.35)	300 U/kg/d	400 mg/kg IVIG
Peng, et al., 2021 [44]	45 vs 45	53.3 vs 44.4	(43.35 ± 4.45) vs (46.18 ± 4.72)	(7.47 ± 1.22) vs (7.58 ± 1.04)	(63.45 ± 6.75) vs (65.48 ± 6.12)	15000 U/d	400 mg/kg IVIG
Qi, et al., 2016 [45]	30 vs 30	53.3 vs 50.0	(50.3 ± 26.2) vs (50.9 ± 25.7)	(52.83 ± 16.32) vs (52.11 ± 16.29)	(18.8 ± 2.7) vs (18.1 ± 2.2)	15000 U/d	NAT
Li, et al., 2013 [43]	28 vs 20	53.9	53.49 ± 17.41	n.a.	n.a.	300 U/kg/d	NAT
Dong, et al., 2020 [39]	50 vs 50	60.0 vs 52.0	(56.48 ± 13.58) vs (57.92 ± 12.69)	(39.08 ± 22.15) vs (38.51 ± 20.96)	(14.82 ± 7.74) vs (17.04 ± 7.38)	15000 U/d	NAT
Zhang, et al., 2018 [50]	34 vs 42	61.8 vs 54.8	(54.50 ± 19.53) vs (53.65 ± 15.52)	(30.64 ± 10.19) vs (37.17 ± 1.68)	(20.21 ± 7.10) vs (19.78 ± 6.05)	15000 U/d	NAT
Zhang, et al., 2016 [49]	35 vs 31	48.6 vs 48.4	(56 ± 9) vs (54 ± 8)	(37 ± 8) vs (38 ± 19)	(17 ± 3) vs (17 ± 3)	300 U/kg/d	NAT
Gao, et al., 2011 [41]	21 vs 22	66.7 vs 63.6	(43.10 ± 21.25) vs (41.74 ± 17.65)	(25.14 ± 7.09) vs (26.13 ± 7.11)	(21.93 ± 8.34) vs (23.47 ± 10.26)	300 U/kg/d	400 mg/kg IVIG
Yang, et al., 2015 [48]	30 vs 30	53.3	45.2 ± 12.7	(34.98 ± 0.64) vs (34.31 ± 0.78)	n.a.	300 U/kg/d	NAT
Yan, et al., 2019 [47]	42 vs 42	54.8 vs 52.4	(59.13 ± 0.37) vs (59.14 ± 0.39)	(25.49 ± 2.53) vs (25.52 ± 2.51)	(18.35 ± 2.14) vs (18.31 ± 2.16)	300 U/kg/d	NAT
Wang, et al., 2019 [46]	63 vs 39	61.9 vs 61.5	(57.2 ± 21.2) vs (56.9 ± 18.3)	(28.7 ± 9.7) vs (27.5 ± 14.1)	(22.6 ± 6.1) vs (23.0 ± 4.6)	300 U/kg/d	400 mg/kg IVIG

APACHE II, acute physiology, age, chronic health evaluation II; PLT, platelet; rhTPO, recombinant human thrombopoietin; IVIG; intravenous immunoglobulin; NAT, no additional treatment; n.a., not applicable. APACHE III for severity assessment.